RHAPSODY is the first IL-1 antagonist clinical trial in pericarditis in which all patients were treated with monotherapy (the Anakinra Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP) tudy did not require discontinuation of colchicine treatment during the randomised-withdrawal period).23 Interestingly, the RHAPSODY investigators made the transition to rilonacept monotherapy in less than the maximum time stipulated by the protocol. Here, IL1A is linked to pericarditis.